GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 7,900 shares of GRAIL stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $85.01, for a total value of $671,579.00. Following the completion of the transaction, the chief financial officer owned 253,083 shares in the company, valued at $21,514,585.83. This represents a 3.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
GRAIL Price Performance
GRAL traded down $0.63 on Monday, hitting $79.37. The company had a trading volume of 555,941 shares, compared to its average volume of 781,912. The stock has a fifty day moving average price of $71.28 and a 200-day moving average price of $63.22. GRAIL, Inc. has a 12-month low of $30.82 and a 12-month high of $118.84.
GRAIL (NASDAQ:GRAL – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million during the quarter, compared to analyst estimates of $42.39 million. Research analysts anticipate that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.
Institutional Trading of GRAIL
Analyst Ratings Changes
Several research firms have issued reports on GRAL. The Goldman Sachs Group started coverage on shares of GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Mizuho boosted their target price on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $67.78.
Read Our Latest Analysis on GRAIL
About GRAIL
GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.
Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.
Featured Articles
- Five stocks we like better than GRAIL
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
